The use of monoclonal antibodies to determine progesterone receptor status increases the predictive value of immunohistochemical analysis with respect to the response of human tumors to hormonal modulation. Historically, estrogen receptor-positive/progesterone receptor-positive breast carcinoma patients have demonstrated a better response to endocrine therapy than estrogen receptor-positive/ progesterone receptor-negative patients.
